CB2 receptor in the CNS: From immune and neuronal modulation to behavior.


Journal

Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090

Informations de publication

Date de publication:
07 2023
Historique:
received: 30 12 2022
revised: 20 03 2023
accepted: 06 05 2023
medline: 5 6 2023
pubmed: 11 5 2023
entrez: 10 5 2023
Statut: ppublish

Résumé

Despite low levels of cannabinoid receptor type 2 (CB2R) expression in the central nervous system in human and rodents, a growing body of evidence shows CB2R involvement in many processes at the behavioral level, through both immune and neuronal modulations. Recent in vitro and in vivo evidence have highlighted the complex role of CB2R under physiological and inflammatory conditions. Under neuroinflammatory states, its activation seems to protect the brain and its functions, making it a promising target in a wide range of neurological disorders. Here, we provide a complete and updated overview of CB2R function in the central nervous system of rodents, spanning from modulation of immune function in microglia but also in other cell types, to behavior and neuronal activity, in both physiological and neuroinflammatory contexts.

Identifiants

pubmed: 37164044
pii: S0149-7634(23)00195-1
doi: 10.1016/j.neubiorev.2023.105226
pii:
doi:

Substances chimiques

Receptor, Cannabinoid, CB2 0
Receptor, Cannabinoid, CB1 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105226

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Competing interests The authors declare no competing interests.

Auteurs

Wanda Grabon (W)

Université Claude Bernard Lyon 1, CNRS, Inserm, Centre de Recherche en Neurosciences de Lyon, U10208 UMR5292, TIGER Team, F-69500 Bron, France; Epilepsy Institute IDEE, 59 boulevard Pinel, F-69500 Bron, France. Electronic address: wanda.grabon@univ-lyon1.fr.

Sylvain Rheims (S)

Université Claude Bernard Lyon 1, CNRS, Inserm, Centre de Recherche en Neurosciences de Lyon, U10208 UMR5292, TIGER Team, F-69500 Bron, France; Epilepsy Institute IDEE, 59 boulevard Pinel, F-69500 Bron, France; Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, France.

Jonathon Smith (J)

Université Claude Bernard Lyon 1, CNRS, Inserm, Centre de Recherche en Neurosciences de Lyon, U10208 UMR5292, TIGER Team, F-69500 Bron, France; Epilepsy Institute IDEE, 59 boulevard Pinel, F-69500 Bron, France.

Jacques Bodennec (J)

Université Claude Bernard Lyon 1, CNRS, Inserm, Centre de Recherche en Neurosciences de Lyon, U10208 UMR5292, TIGER Team, F-69500 Bron, France; Epilepsy Institute IDEE, 59 boulevard Pinel, F-69500 Bron, France.

Amor Belmeguenai (A)

Université Claude Bernard Lyon 1, CNRS, Inserm, Centre de Recherche en Neurosciences de Lyon, U10208 UMR5292, TIGER Team, F-69500 Bron, France; Epilepsy Institute IDEE, 59 boulevard Pinel, F-69500 Bron, France.

Laurent Bezin (L)

Université Claude Bernard Lyon 1, CNRS, Inserm, Centre de Recherche en Neurosciences de Lyon, U10208 UMR5292, TIGER Team, F-69500 Bron, France. Electronic address: laurent.bezin@univ-lyon1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH